High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naïve perinatally-infected children and adolescents with HIV-1 subtype C infection

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Neogi, Ujjwal ^a,b   Sahoo, Pravat Nalini ^b   De Costa, Ayesha ^a   Shet, Anita ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

HIV 1 perinatal transmission; India; Subtype C; Viral dynamics

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; AGE; ANTIVIRAL RESISTANCE; ARTICLE; ASYMPTOMATIC INFECTION; CD4 LYMPHOCYTE COUNT; CHILD; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; GENE MUTATION; GENETIC DISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERINATAL INFECTION; PHYLOGENY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; SEQUENCE ANALYSIS; STRUCTURAL GENE; VERTICAL TRANSMISSION; VIREMIA; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ASYMPTOMATIC DISEASES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MALE; VIRAL LOAD; VIREMIA;

EID: 84869868237     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-317     Document Type: Article

References (40)

1. National AIDS Control Organization, Annual Report, 2009-2010. http://nacoonline.org/upload/AR%202009-10/NACO_AR_English%20corrected.pdf.
2. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999, 73:10489-10502. 113104, 10559367.
3. Ganeshan S, Dickover RE, Korber BT, Bryson YJ, Wolinsky SM. Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol 1997, 71:663-677. 191099, 8985398.
4. McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, Karthas N, Burchett SK. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996, 15:1087-1091. 10.1097/00006454-199612000-00006, 8970217.
5. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, Rich K, Handelsman E, Diaz C, Pagano M, Smeriglio V, Kalish LA. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997, 336:1337-1342. 10.1056/NEJM199705083361901, 9134873.
6. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921-929. 10.1056/NEJM200003303421303, 10738050.
7. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008, 22:2179-2185. 10.1097/QAD.0b013e328312c756, 2661869, 18832881.
8. Novitsky V, Ndung'u T, Wang R, Bussmann H, Chonco F, Makhema J, DeGruttola V, Walker BD, Essex M. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS 2011, 25:1515-1522. 10.1097/QAD.0b013e3283471eb2, 21505307.
9. Dyer JR, Kazembe P, Vernazza PL, Gilliam BL, Maida M, Zimba D, Hoffman IF, Royce RA, Schock JL, Fiscus SA, Cohen MS, Eron JJ. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998, 177:1742-1746. 10.1086/517436, 9607862.
10. Neogi U, Prarthana BS, Gupta S, D'souza G, De Costa A, Kuttiatt VS, Arumugam K, Shet A. Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naïve individuals in Bangalore, India. AIDS Res Hum Retroviruses 2010, 26:1097-1101. 10.1089/aid.2010.0092, 20836706.
11. Thorat SR, Chaturbhuj DN, Hingankar NK, Chandrasekhar V, Koppada R, Datkar SR, Srikantiah P, Garg R, Kabra S, Haldar P, Reddy DC, Bachani D, Tripathy SP, Paranjape RS. Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India. AIDS Res Hum Retroviruses 2011, 27:1291-1297. 10.1089/aid.2011.0036, 21568760.
12. Chaturbhuj DN, Hingankar NK, Srikantiah P, Garg R, Kabra S, Deshmukh PS, Jadhav SD, Thorat SR, Datkar SR, Mehta P, Ingole N, Mathur M, Ramachandran A, Haldar P, Reddy DC, Bachani D, Rao S, Tripathy SP, Paranjape RS. Transmitted HIV drug resistance among HIV-infected voluntary counselling and testing centers (VCTC) clients in Mumbai, India. AIDS Res Hum Retroviruses 2010, 26:927-932. 10.1089/aid.2010.0032, 20704495.
13. Hall TA. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999, 41:95-98.
14. Sinha S, Ahmad H, Shekhar RC, Kumar N, Dar L, Samantaray JC, Sharma SK, Bhargava A, Pandey RM, Mitsuyasu RL, Fahey JL. Prevalence of HIV drug resistance mutations in HIV type 1 isolates in antiretroviral therapy naïve population from northern India. AIDS Res Treat 2012, 2012:905823. 3312221, 22496972.
15. Deshpande A, Karki S, Recordon-Pinson P, Flury HJ. Drug resistance mutations in HIV type 1 isolates from naive patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India. AIDS Res Hum Retroviruses 2011, 27:1345-1347. 10.1089/aid.2011.0066, 21453163.
16. Iqbal HS, Solomon SS, Madhavan V, Solomon S, Balakrishnan P. Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India. J Int Assoc Physicians AIDS Care (Chic) 2009, 8:323-327.
17. Rajesh L, Karunaianantham R, Narayanan PR, Swaminathan S. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients. AIDS Res Hum Retroviruses 2009, 25:1179-1185. 10.1089/aid.2009.0110, 19895208.
18. Kandathil AJ, Kannangai R, Abraham OC, Rupali P, Pulimood SA, Verghese VP, Grant P, Pillay D, Sridharan G. The frequency of HIV-I drug resistance mutations among treatment-naive individuals at a tertiary care centre in south India. Int J STD AIDS 2009, 20:522-526. 10.1258/ijsa.2008.008403, 19625581.
19. Balakrishnan P, Kumarasamy N, Kantor R, Solomon S, Vidya S, Mayer KH, Newstein M, Thyagarajan SP, Katzenstein D, Ramratnam B. HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses 2005, 21:301-305. 10.1089/aid.2005.21.301, 15943572.
20. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Mol Biol Evol 2011, 28:2731-2739. 10.1093/molbev/msr121, 3203626, 21546353.
21. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC. Full length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999, 73:152-160. 103818, 9847317.
22. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009, 4:e4724. 10.1371/journal.pone.0004724, 2648874, 19266092.
23. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011, 19:156-164.
24. Neogi U, Bontell I, Shet A, De Costa A, Gupta S, Diwan V, Laishram RS, Wanchu A, Ranga U, Banerjea AC, Sönnerborg A. Molecular epidemiology of HIV-1 subtypes in India: Origin and evolutionary history of the predominant subtype C. PLoS ONE 2012, 7(6):e39819. 10.1371/journal.pone.0039819, 3387228, 22768132.
25. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA, CHER Study Team Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359:2233-2244. 10.1056/NEJMoa0800971, 2950021, 19020325, CHER Study Team.
26. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, McIntyre J, Lingappa JR, Celum C, Partners in Prevention HSV/HIV Transmission Study Team Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010, 375:2092-2098. 10.1016/S0140-6736(10)60705-2, 2922041, 20537376, Partners in Prevention HSV/HIV Transmission Study Team.
27. Soundararajan L, Karunaianandham R, Jauvin V, Schrive MH, Ramachandran R, Narayanan PR, Fleury HJ, Swaminathan S. Characterization of HIV-1 isolates from antiretroviral drug-naive children in southern India. AIDS Res Hum Retroviruses 2007, 23:1119-1126. 10.1089/aid.2007.0012, 17919107.
28. Sehgal S, Pasricha N, Singh S. High rate of mutation K103N causing resistance to nevirapine in Indian children with acquired immunodeficiency syndrome. Ind J Med Microbiol 2008, 26:372-374.
29. Neogi U, Shet A, Shamsundar R, Ekstrand ML. Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance. AIDS 2011, 25:1123-1126. 10.1097/QAD.0b013e328346269f, 21505320.
30. Pedrosa C, Queiroz AT, Alcantara LC, Drexler JF, Diaz RS, Weyll N, Brites C. High prevalence of primary antiretroviral resistance among HIV-1 infected adults and children in Bahia, a northeast state of Brazil. J Acquir immune Defic Syndr 2007, 45:251-253. 10.1097/QAI.0b013e318050d8b0, 17527096.
31. Charpentier C, Gody JC, Tisserand P, Matta M, Péré H, Fournier J, Mbitikon O, Bélec L. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic. Antivir Ther 2011, 16:1347-1350. 10.3851/IMP1896, 22155917.
32. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F, Ghent Group on HIV in Women and Children Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007, 36:1009-1021. 10.1093/ije/dym104, 17533166, Ghent Group on HIV in Women and Children.
33. De Mulder M, Yebra G, Martin L, Prieto L, Mellado MJ, Rojo P, Muñoz-Fernández M, Jiménez de Ory S, Ramos JT, Holguín A, Madrid cohort of HIV-infected children Drug resistance prevalence and HIV-1 variant characterization in the naïve and pretreated HIV-1- infected paediatric population in Madrid, Spain. J Antimicrob Chemother 2011, 66:2362-2371. 10.1093/jac/dkr305, 21810838, Madrid cohort of HIV-infected children.
34. van Zyl GU, Cotton MF, Claassen M, Abrahams C, Preiser W. Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa. Pediatr Infect Dis J 2010, 29:370-371.
35. Poon AFY, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez B, Boswell SL, Frost SD, Haubrich RH. Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load. PLoS ONE 2011, 6:e21189. 10.1371/journal.pone.0021189, 3118815, 21701595.
36. de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E, van Gemen B, de Boer R, Goudsmit J. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001, 75:595-602. 10.1128/JVI.75.2.595-602.2001, 113955, 11134272.
37. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A 2001, 98:13907-13912. 10.1073/pnas.241300698, 61140, 11698656.
38. Sungkanuparph S, Kiertiburanakul S, Sukasem C, Chantratita W. Discrepancies between WHO 2009 and IAS-USA 2009 lists for determining the rate of transmitted HIV-1 drug resistance: a prospective study. J Acquir Immune Defic Syndr 2012, 59:e3-e5. 10.1097/QAI.0b013e31823ac978, 22156823.
39. Guidelines for surveillance of HIV drug resistance. 2003, http://wwwn.cdc.gov/dls/ila/cd/who-afro/resisguide12_12.pdf.
40. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.